ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) Director Christobel Selecky sold 95,722 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $9.01, for a total value of $862,455.22. Following the transaction, the director owned 32,173 shares of the company’s stock, valued at $289,878.73. The trade was a 74.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christobel Selecky also recently made the following trade(s):
- On Tuesday, June 30th, Christobel Selecky sold 1,000 shares of ImmunityBio stock. The stock was sold at an average price of $9.00, for a total transaction of $9,000.00.
ImmunityBio Stock Performance
NASDAQ:IBRX traded up $0.44 during trading hours on Wednesday, hitting $9.20. The stock had a trading volume of 16,295,448 shares, compared to its average volume of 26,385,029. ImmunityBio, Inc. has a one year low of $1.95 and a one year high of $12.43. The company has a market cap of $9.64 billion, a price-to-earnings ratio of -10.82 and a beta of 0.03. The business’s 50 day moving average is $7.63 and its 200-day moving average is $6.62.
Analyst Upgrades and Downgrades
IBRX has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. BTIG Research restated a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of ImmunityBio in a research report on Tuesday, June 2nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.
Check Out Our Latest Research Report on IBRX
Hedge Funds Weigh In On ImmunityBio
Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Swiss Life Asset Management Ltd bought a new stake in ImmunityBio during the third quarter worth $27,000. WealthPlan Investment Management LLC acquired a new stake in ImmunityBio in the fourth quarter valued at $27,000. Diversify Advisory Services LLC bought a new position in shares of ImmunityBio in the 2nd quarter valued at about $27,000. Kovack Advisors Inc. bought a new position in shares of ImmunityBio in the 4th quarter valued at about $27,000. Finally, Cherry Creek Investment Advisors Inc. acquired a new position in shares of ImmunityBio during the 4th quarter worth about $28,000. 8.58% of the stock is owned by institutional investors.
About ImmunityBio
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Featured Articles
- Five stocks we like better than ImmunityBio
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
